Palvella Therapeutics, Inc. Research and Development Expense
Palvella Therapeutics, Inc. (PVLA) reported Research and Development Expense of $12.47 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-04
- Palvella Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $12.47M, a 143.71% increase year-over-year.
- Palvella Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $9.33M, a 129.11% increase year-over-year.
- Palvella Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $7.12M, a 180.02% increase year-over-year.
- Palvella Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $6.53M, a 105.15% increase year-over-year.
- Palvella Therapeutics, Inc. research and development expense for fiscal 2025 was $22.84M, a 180.22% increase from fiscal 2024.
- Palvella Therapeutics, Inc. research and development expense for fiscal 2024 was $8.15M, a 7.30% decline from fiscal 2023.
- Palvella Therapeutics, Inc. research and development expense for fiscal 2023 was $8.79M, a 83.40% decline from fiscal 2022.
- Palvella Therapeutics, Inc. research and development expense for fiscal 2022 was $52.98M, a 20.51% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $12.47M 10-Q · filed 2026-08-04 | $21.81M 10-Q · filed 2026-08-04 | $28.93M derived: sum of 3 quarters · filed 2026-08-04 | $35.46M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $9.33M 10-Q · filed 2026-05-07 | $16.45M derived: sum of 2 quarters · filed 2026-05-07 | $22.98M derived: sum of 3 quarters · filed 2026-05-07 | $28.10M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $7.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $13.65M derived: sum of 2 quarters · filed 2026-03-31 | $18.77M derived: sum of 3 quarters · filed 2026-08-04 | $22.84M 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | $6.53M 10-Q · filed 2025-11-12 | $11.65M derived: sum of 2 quarters · filed 2026-08-04 | $15.72M 10-Q · filed 2025-11-12 | $18.26M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $5.12M 10-Q · filed 2026-08-04 | $9.19M 10-Q · filed 2026-08-04 | $11.73M derived: sum of 3 quarters · filed 2026-08-04 | $14.92M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $4.07M 10-Q · filed 2026-05-07 | $6.62M derived: sum of 2 quarters · filed 2026-05-07 | $9.80M derived: sum of 3 quarters · filed 2026-05-07 | $11.24M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $2.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $5.72M derived: sum of 2 quarters · filed 2026-03-31 | $7.17M derived: sum of 3 quarters · filed 2026-03-31 | $8.15M 10-K · filed 2026-03-31 | ||||
| 2024-09-30 | $3.18M 10-Q · filed 2025-11-12 | $4.62M derived: sum of 2 quarters · filed 2025-11-12 | $5.61M 10-Q · filed 2025-11-12 | -$22.95M derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | $1.44M 10-Q · filed 2025-08-14 | $751.00K 10-Q · filed 2024-08-14 | $2.43M 10-Q · filed 2025-08-14 | $1.97M 10-Q · filed 2024-08-14 | -$26.13M derived: sum of 3 quarters · filed 2025-08-14 | -$16.53M derived: sum of 4 quarters · filed 2025-08-14 | ||
| 2024-03-31 | $984.00K 10-Q · filed 2025-05-15 | $1.22M 10-Q · filed 2024-05-15 | -$27.57M derived: sum of 2 quarters · filed 2025-05-15 | -$17.98M derived: sum of 3 quarters · filed 2025-05-15 | -$3.65M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | -$28.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$18.96M derived: sum of 2 quarters · filed 2025-03-31 | -$4.63M derived: sum of 3 quarters · filed 2025-03-31 | $8.79M 10-K · filed 2025-03-31 | $41.80M 10-K · filed 2024-03-29 | |||
| 2023-09-30 | $9.60M 10-Q · filed 2023-11-14 | $23.92M derived: sum of 2 quarters · filed 2024-08-14 | $37.35M 10-Q · filed 2023-11-14 | $50.73M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-06-30 | $14.33M 10-Q · filed 2024-08-14 | $27.75M 10-Q · filed 2024-08-14 | $41.13M derived: sum of 3 quarters · filed 2024-08-14 | $54.72M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | $13.42M 10-Q · filed 2024-05-15 | $26.80M derived: sum of 2 quarters · filed 2024-05-15 | $40.39M derived: sum of 3 quarters · filed 2024-05-15 | $52.34M derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | $13.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $26.97M derived: sum of 2 quarters · filed 2024-03-29 | $38.92M derived: sum of 3 quarters · filed 2024-03-29 | $52.98M 10-K · filed 2024-03-29 | ||||
| 2022-09-30 | $13.59M 10-Q · filed 2023-11-14 | $25.54M derived: sum of 2 quarters · filed 2023-11-14 | $39.60M 10-Q · filed 2023-11-14 | $54.96M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $11.95M 10-Q · filed 2023-08-10 | $26.01M 10-Q · filed 2023-08-10 | $41.37M derived: sum of 3 quarters · filed 2023-08-10 | $60.31M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $14.07M 10-Q · filed 2023-05-11 | $29.42M derived: sum of 2 quarters · filed 2023-05-11 | $48.36M derived: sum of 3 quarters · filed 2023-05-11 | $64.16M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $15.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $34.29M derived: sum of 2 quarters · filed 2023-03-31 | $50.09M derived: sum of 3 quarters · filed 2023-03-31 | $66.66M 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $18.94M 10-Q · filed 2022-11-04 | $34.74M derived: sum of 2 quarters · filed 2022-11-04 | $51.30M 10-Q · filed 2022-11-04 | $61.92M derived: sum of 4 quarters · filed 2022-11-04 | ||||
| 2021-06-30 | $15.80M 10-Q · filed 2022-08-04 | $32.36M 10-Q · filed 2022-08-04 | $42.98M derived: sum of 3 quarters · filed 2022-08-04 | $54.80M derived: sum of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | $16.56M 10-Q · filed 2022-05-11 | $27.18M derived: sum of 2 quarters · filed 2022-05-11 | $39.00M derived: sum of 3 quarters · filed 2022-05-11 | $50.34M derived: sum of 4 quarters · filed 2022-05-11 | ||||
| 2020-12-31 | $10.62M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $22.44M derived: sum of 2 quarters · filed 2022-03-02 | $33.77M derived: sum of 3 quarters · filed 2022-03-02 | $46.53M 10-K · filed 2022-03-02 | ||||
| 2020-09-30 | $11.82M 10-Q · filed 2021-11-02 | $23.16M derived: sum of 2 quarters · filed 2021-11-02 | $35.91M 10-Q · filed 2021-11-02 | $50.03M derived: sum of 4 quarters · filed 2021-11-02 | ||||
| 2020-06-30 | $11.33M 10-Q · filed 2021-08-05 | $24.09M 10-Q · filed 2021-08-05 | $38.21M derived: sum of 3 quarters · filed 2021-08-05 | $51.42M derived: sum of 4 quarters · filed 2021-08-05 | ||||
| 2020-03-31 | $12.76M 10-Q · filed 2021-05-17 | $26.87M derived: sum of 2 quarters · filed 2021-05-17 | $40.09M derived: sum of 3 quarters · filed 2021-05-17 | $53.46M derived: sum of 4 quarters · filed 2021-05-17 | ||||
| 2019-12-31 | $14.12M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $27.33M derived: sum of 2 quarters · filed 2021-03-31 | $40.70M derived: sum of 3 quarters · filed 2021-03-31 | $55.00M 10-K · filed 2021-03-31 | ||||
| 2019-09-30 | $13.21M 10-Q · filed 2020-11-04 | $26.58M derived: sum of 2 quarters · filed 2020-11-04 | $40.88M 10-Q · filed 2020-11-04 | $53.88M derived: sum of 4 quarters · filed 2020-11-04 | ||||
| 2019-06-30 | $13.37M 10-Q · filed 2020-08-10 | $27.67M 10-Q · filed 2020-08-10 | $40.67M derived: sum of 3 quarters · filed 2020-08-10 | $52.07M derived: sum of 4 quarters · filed 2020-08-10 | ||||
| 2019-03-31 | $14.30M 10-Q · filed 2020-05-11 | $27.29M derived: sum of 2 quarters · filed 2020-05-11 | $38.70M derived: sum of 3 quarters · filed 2020-05-11 | $47.85M derived: sum of 4 quarters · filed 2020-05-11 | ||||
| 2018-12-31 | $13.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $24.40M derived: sum of 2 quarters · filed 2020-03-13 | $33.55M derived: sum of 3 quarters · filed 2020-03-13 | $41.49M 10-K · filed 2020-03-13 | ||||
| 2018-09-30 | $11.40M 10-Q · filed 2019-11-12 | $20.56M derived: sum of 2 quarters · filed 2019-11-12 | $28.49M 10-Q · filed 2019-11-12 | $33.76M derived: sum of 4 quarters · filed 2019-11-12 | ||||
| 2018-06-30 | $9.15M 10-Q · filed 2019-08-09 | $17.09M 10-Q · filed 2019-08-09 | $22.36M derived: sum of 3 quarters · filed 2019-08-09 | $28.62M derived: sum of 4 quarters · filed 2019-08-09 | ||||
| 2018-03-31 | $7.94M 10-Q · filed 2019-05-10 | $13.21M derived: sum of 2 quarters · filed 2019-05-10 | $19.46M derived: sum of 3 quarters · filed 2019-05-10 | $24.86M derived: sum of 4 quarters · filed 2019-05-10 | ||||
| 2017-12-31 | $5.27M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $11.53M derived: sum of 2 quarters · filed 2019-03-18 | $16.93M derived: sum of 3 quarters · filed 2019-03-18 | $22.29M 10-K · filed 2019-03-18 | ||||
| 2017-09-30 | $6.26M 10-Q · filed 2018-11-07 | $6.26M 10-Q · filed 2017-11-13 | $11.65M derived: sum of 2 quarters · filed 2018-11-07 | $17.02M 10-Q · filed 2018-11-07 | $17.01M 10-Q · filed 2017-11-13 | $23.93M derived: sum of 4 quarters · filed 2018-11-07 | ||
| 2017-06-30 | $5.40M 10-Q · filed 2018-08-09 | $5.40M 10-Q · filed 2017-08-11 | $10.76M 10-Q · filed 2018-08-09 | $10.76M 10-Q · filed 2017-08-11 | $17.67M derived: sum of 3 quarters · filed 2018-08-09 | $22.30M derived: sum of 4 quarters · filed 2018-08-09 | ||
| 2017-03-31 | $5.36M 10-Q · filed 2018-05-10 | $5.36M 10-Q · filed 2017-05-15 | $12.28M derived: sum of 2 quarters · filed 2018-05-10 | $16.90M derived: sum of 3 quarters · filed 2018-05-10 | $21.40M derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2016-12-31 | $6.92M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $11.54M derived: sum of 2 quarters · filed 2018-03-15 | $16.04M derived: sum of 3 quarters · filed 2018-03-15 | $19.70M 10-K · filed 2018-03-15 | $19.70M 10-K · filed 2017-03-30 | |||
| 2016-09-30 | $4.62M 10-Q · filed 2017-11-13 | $9.12M derived: sum of 2 quarters · filed 2017-11-13 | $12.78M 10-Q · filed 2017-11-13 | $15.72M derived: sum of 4 quarters · filed 2017-11-13 | ||||
| 2016-06-30 | $4.50M 10-Q · filed 2017-08-11 | $8.16M 10-Q · filed 2017-08-11 | $11.10M derived: sum of 3 quarters · filed 2017-08-11 | $13.15M derived: sum of 4 quarters · filed 2017-08-11 | ||||
| 2016-03-31 | $3.66M 10-Q · filed 2017-05-15 | $6.60M derived: sum of 2 quarters · filed 2017-05-15 | $8.65M derived: sum of 3 quarters · filed 2017-05-15 | $10.38M derived: sum of 4 quarters · filed 2017-05-15 | ||||
| 2015-12-31 | $2.94M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30 | $4.99M derived: sum of 2 quarters · filed 2017-03-30 | $6.72M derived: sum of 3 quarters · filed 2017-03-30 | $8.24M 10-K · filed 2017-03-30 | ||||
| 2015-09-30 | $2.05M 10-Q · filed 2016-11-10 | $3.78M derived: sum of 2 quarters · filed 2016-11-10 | $5.30M 10-Q · filed 2016-11-10 | $7.63M derived: sum of 4 quarters · filed 2016-11-10 | ||||
| 2015-06-30 | $1.73M 10-Q · filed 2016-08-11 | $3.25M 10-Q · filed 2016-08-11 | $5.58M derived: sum of 3 quarters · filed 2016-08-11 | $6.51M derived: sum of 4 quarters · filed 2016-08-11 | ||||
| 2015-03-31 | $1.52M 10-Q · filed 2016-05-12 | $3.86M derived: sum of 2 quarters · filed 2016-05-12 | $4.78M derived: sum of 3 quarters · filed 2016-05-12 | $5.90M derived: sum of 4 quarters · filed 2016-05-12 | ||||
| 2014-12-31 | $2.33M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | $3.26M derived: sum of 2 quarters · filed 2016-03-23 | $4.38M derived: sum of 3 quarters · filed 2016-03-23 | $5.60M 10-K · filed 2016-03-23 | ||||
| 2014-09-30 | $926.60K 10-Q · filed 2015-11-13 | $2.05M derived: sum of 2 quarters · filed 2015-11-13 | $3.27M 10-Q · filed 2015-11-13 | |||||
| 2014-06-30 | $1.12M 10-Q · filed 2015-08-13 | $2.34M 10-Q · filed 2015-08-13 | ||||||
| 2014-03-31 | $1.22M 10-Q · filed 2015-05-14 | |||||||
| 2013-12-31 | $9.41M 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |